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in two arms: 1. taking a dosage of 1 mg/day for other 4 weeks; 2. taking a
dosage of 2 mg 3 times a week for 4 weeks. In 9 pts, who experienced a lack
of action of Procalupride (possible receptional phenomenon), we decided to
make a wash out of the drug for 2 weeks (6 pts) or to double the dosage at 4
mg/day (3 pts), and than to follow up them for a further 4 weeks period.
Results: 4 pts out of 28 experienced signiﬁcant side effects (mainly headache
or abdominal pain) and dropped out, as well as 2 for personal reasons.
Overall, 22 pts were evaluable for the results: the improvement in SCBMs
was reached over the 4 weeks of treatment in 16 pts with an improvement in
both symptom relief and quality of life. In group 1 of retraitment (14 pts),
10 followed experienced after 4 weeks of 1 mg/day administration the some
results compared with 4 out of 8 in group 2. In the group of 9 pts with lack of
action 5 out of 6 restored the beneﬁt after the wash out of the drug, compared
with the 3 patients taking 4 mg daily.
Conclusions: Procalupride confrimed its efﬁcacy in the daily life experience,
with a reasonable percentage of side effects, leading to signiﬁcant improve-
ment in both symptoms relief and quality of life of patients. Further studies
are necessary to identify the best approach to maintain clinical beneﬁts.
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CHRONIC CONSTIPATION IS A RISK FACTOR FOR METABOLIC
SYNDROME
G. Sarnelli, R. D’Aniello, M. Pesce, F.P. Zito, A. D’Alessandro, M. Della
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Background and aim: A recent epidemiologic survey in the U.S. provides
indirect evidence that constipation is a risk factor for cardiovascular disease
in postmenopausal females. To characterize the related factors involved in
and to further analyse if this assumption also applies to an Italian population,
we studied the impact of chronic constipation on ischemic cardiopathy and
predisposing risk factors in a large population of female patients in a primary
care setting.
Material and methods: We retrospectively evaluated 754 female patients
(mean age 46±20 years) on data ﬁle of a primary care setting. All sub-
jects requiring medical referral for constipation were screened and presence
of chronic constipation was conﬁrmed by standardized questionnaires. The
presence of clinical and/or instrumental diagnosis of ischemic cardiopathy,
metabolic syndrome, diabetes and blood hypertension was scored in patients
with and without chronic constipation. In all patients the consumption of
drugs potentially delaying colonic transit (calcium channel blockers and
beta blockers) was recorded. Patients on opioid or analgesic treatment were
excluded.
Results: The overall prevalence of chronic constipation was 9.4% (71/754)
with the age being similar in patients with and without constipation (46±19
vs. 51±22, p=NS). The prevalence of metabolic syndrome was signiﬁcantly
higher in subjects with chronic constipation (5/66 vs 16/667, OR=3.1, 95%
CI 1.1–8.9, p=0.03). Conversely, prevalence of diabetes, blood hypertension,
ischemic cardiopathy was similar in patients with and without constipation
(59/624 vs 10/61; 204/478 vs 28/43; 46/637 vs 6/65, respectively p= all NS).
No signiﬁcant difference was also observed as far as calcium channel blockers
(64/619 vs 9/62) and beta blockers (81/602 vs 9/62) consumption in patients
with or without constipation respectively.
Conclusions: We showed that chronic constipation is a risk factor for
metabolic syndrome in female patients. Although we did not ﬁnd any signif-
icant association between chronic constipation and ischemic cardiopathy, our
ﬁndings support the hypothesis that constipation may act as cardiovascular
risk factor. Whether this association is dependent on dietary or hormonal
factors deserves further investigation.
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Background and aim: Symptoms of irritable bowel syndrome (IBS) have
been associated to altered motility and sensation. In constipated prevalent-IBS
patients, a clear association between bowel habit and abdominal pain remains
to be established, and it is not known whether factors related to patients daily
life may play a role in symptoms generation.
Our aim was to evaluate the association between abdominal pain, bowel
habit, demographic factors, alimentary/voluptuary habits and colonic transit
in constipated-IBS patients.
Material and methods: 68 patients complaining of chronic constipation were
selected on the basis of the Rome 3 criteria for IBS. Colonic transit time
(CTT) was studied and alimentary attitudes and smoking habit were recorded.
Presence of mild or severe abdominal pain was scored, as well as the prevalent
pain characteristics, deﬁned as diffuse or localized, chronic or acute, with
cramps or gradually distending. Data were analysed by univariate and stepwise
multiple logistic regression analysis was also used to verify the risk association
between pain and all other variables.
Results: 40 patients were classiﬁed as constipated and 28 had alternating
evacuation. Constipated patients had a lower scholar degree, consumed more
laxatives, had a longer transit time in the right colon and scored more
chronic pain than alternating ones, but it was not conﬁrmed by multivariate
analysis. When severity of abdominal pain was used as discriminating factor,
a signiﬁcant number of subjects reporting severe pain were males (16/30 vs
4/38, p<0.01) and smokers (20/30 vs 4/38, p<0.001). Multivariate analysis
conﬁrmed that only smoking was an independent factor associated with severe
abdominal pain (OR 14.3, CI 2–99, p= 0.007).
Conclusions: Abdominal pain is similarly reported by constipated or al-
ternating IBS patients and it is not associated with colonic transit time
or demographics. Smoking is the only factor constantly and independently
associated to severe abdominal pain. As smoking does not seem likely to
affect colonic transit time we suggest that smoking may act on the visceral
perception in IBS-constipated patients.
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Background and aim: Irritable bowel syndrome (IBS) is a functional gas-
trointestinal disorder (GFD). In the pathogenesis are implicated alterations of
GUT microbiota, motility, intestinal immunity and inﬂammation, and recently
was given a major role to changes in intestinal permeability. Patient with IBS
has poor quality of life. For treatment of IBS we use probiotics, antibiotics
and recent studies including meta-analysis have demonstrated the efﬁcacy of
tricyclic antidepressant (TCA) in particular amitriptyline.
The aim of our study was to evaluate the efﬁcacy of amitriptyline not only
to improve the quality of life of patients but also in improving intestinal
permeability.
Material and methods: We enrolled 20 pts (10F, 10M; mean age 38±4yrs)
with IBS according to Roma III criteria. All patients underwent to intestinal
permeability with chromium EDTA test. Quality of life was analyzed by SF36
test. Then, we administered amytriptiline 10 mg po twice daily for 30 days.
At the end of treatment we repeated intestinal permeability with chromium
EDTA test and SF36 test.
Results: All items analyzed by SF36 were lower compared to the normal
values for the general Italian population. Mean Mental Health Index (MHI)
and Physical Health Index (PHI), the two main scores of SF 36, were both
